Search Results for: DRUG DEVELOPMENT Human Challenge Studies
Articles
EXCIPIENT UPDATE - Soluplus®: An Understanding of Supersaturation From Amorphous Solid Dispersions January 6, 2015
Oksana Tsinman, Konstantin Tsinman, PhD, and Shaukat Ali, PhD, describe the application of a hydrophilic polymeric solubilizer in solid dispersions of a model drug carbamazepine. The scope of this study is limited to understanding of hydrophilic polymers and their behaviors on amorphous dispersions.
Hemispherx’s Ampligen Provides Anti-Tumor Activity Analogous to Emerging Immune Checkpoint Inhibitors December 16, 2014
Philadelphia, PA, December 16, 2014: Hemispherx Biopharma, Inc. (NYSE MKT: HEB) (the “Company” or “Hemispherx”), recently announced further progress on developing...QUALITY-BY-DESIGN - Quality-by-Design: The Good, The Bad, The Inevitable October 2, 2014
Michael Lowenborg believes in essence, QbD can be interpreted as a way to maximize time and cost savings by better understanding the components and processes necessary to optimize a drug product’s safety, efficacy, and quality at every stage in development.
NANOEMULSION FORMULATIONS - Nanoemulsion Formulations for Injection & Oral Administration October 2, 2014
Troy M. Harmon, MS, MBA, and Jingjun Huang, PhD, use Ascendia’s EmulSol technology to develop a novel oil-in-water nanoemulsion formulation of clopidogrel whereby the free-base form of clopidogrel has acceptable solubility in the oil phase, and is protected from chemical degradation.
BIOAVAILABILITY ENHANCEMENT - Potential for Expanding Chemical Space September 2, 2014
Marshall Crew, PhD, focuses on considering what might be achieved if we borrow best practices and processes that have assisted other industries facing growing complexity, in fact, much of the advances in accelerating our solubilization processes are already borrowed from other industries, in many cases even the technologies.
SPECIAL FEATURE - Patients & Physicians Desire Transdermal, Topical & Subcutaneous Delivery July 9, 2014
Contributor Cindy H. Dubin recently interviewed several topical, transdermal, and subcutaneous product manufacturers to find out how they are working with patients and physicians to develop delivery systems that meet their needs for comfort, compliance, and more effective delivery.
Can Regenerative Medicine be the Cure for Cancer & Other Deadly Diseases? June 21, 2014
Regenerative medicine has the potential to transform healthcare all over the world and usher human health into a new era...Can Regenerative Medicine be the Cure for Cancer & Other Deadly Diseases? June 19, 2014
Regenerative medicine has the potential to transform healthcare all over the world and usher human health into a new era...EXECUTIVE INTERVIEW - The Integration of Bend Research With Capsugel Dosage Form Solutions (DFS) June 4, 2014
Drug Development Executive: Rod Ray, former Bend Research CEO and now a member of Capsugel’s Scientific and Business Advisory Board, talks about the enhanced capabilities of Capsugel DFS and the advantages offered to companies developing new and/or enhanced medicines.
EXECUTIVE INTERVIEW - 4P Therapeutics: Developing New & Innovative Transdermal Products June 3, 2014
Drug Development Executive: Steven Damon, Founder of 4P Therapeutics, discusses his vision for the company and how 4P intends to create new and innovative transdermal products that meet the needs of patients, physicians, and payers.
SPECIAL FEATURE - Prefilled Syringes & Parenteral Contract Manufacturing - Product Differentiation Is Critical May 8, 2014
Contributor Cindy H. Dubin speaks with several of these suppliers and manufacturers about the importance of customization and differentiation as the key to pharma companies staying competitive in the prefilled syringe space.
Promethera Biosciences & EMD Millipore Join Forces March 17, 2014
Promethera Biosciences recently announced a collaboration with EMD Millipore to develop an improved ready-to-use microfluidic perfusion liver assay. This new...PREFILLABLE SYRINGE TECHNOLOGY - BD Neopak - Delivering the Next Generation in Glass Prefillable Syringes January 8, 2014
Justin M. Wright, PhD, and Herve Soukiassian highlight significant development and commercial manufacturing investments in glass PFS container technology for the biotech industry with three key areas of focus: reducing overall variability, reducing SbVPs, and increasing glass strength and durability performance.
MANAGEMENT INSIGHT - Six Reasons Why the Affordable Care Act May Be a Bad-Tasting Medicine That Could Heal Our Industry January 7, 2014
Derek Hennecke says that whether you love the Affordable Care Act (ACA) or abhor it, the fact is, there are billions of dollars of government money in play and some industries are going to benefit tremendously.
Adocia Signs Exclusive Nanotechnology License December 17, 2013
Adocia recently announced the signature of an exclusive license agreement with the CNRS, the University Bordeaux I, the Institut Polytechnique...IBM Research & Institute of Bioengineering & Nanotechnology Discover Breakthrough for Breast Cancer Delivery December 2, 2013
Recently, scientists from IBM and Singapore's Institute of Bioengineering and Nanotechnology published a breakthrough drug delivery technique, demonstrating the first...Capsugel's Vcaps Plus HPMC Capsules Enhance Performance for Recently Approved Levomilnacipran November 10, 2013
Capsugel’s Vcaps Plus HPMC (hypromellose) capsules are increasingly the preferred capsule option among pharmaceutical companies looking for innovative dosage forms...FORMULATING PEPTIDES - Novel Formulations for Non-Invasive Delivery & Stabilization of Peptides October 15, 2013
Edward T. Maggio, PhD, examines how alkylsaccharides offer exciting prospects for novel formulations, providing non-invasive delivery, stabilization, and immunogenicity reduction for biotherapeutic products, resulting in broader patient acceptance and compliance and an increase in their acceptance as viable commercial pharmaceuticals.
SPECIAL FEATURE - Hand Held Devices: New Technologies Right the Wrongs of Earlier Devices October 4, 2013
Contributor Cindy H. Dubin highlights in this annual report that new devices are coming to market that not only address the trends of home care and a need for delivering larger doses, but are also cleaning up the spotty reputation of early stage devices.
THERAPEUTIC FOCUS - New Therapeutics for Aggressive Brain Cancers October 3, 2013
Jeffrey Bacha, MBA, says glioblastoma is one of the most common and fatal brain cancers, and new therapies to treat this disease are urgently needed. New approaches, such as vaccines and immunotherapies, have promising results, and to be most effective, will need to be used in combination with a chemotherapeutic.
